Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term Broad microbial components refers to a diverse group of molecules shared by many microorganisms, often referred to as Pathogen-Associated Molecular Patterns (PAMPs). These include structures such as lipopolysaccharides (LPS) from Gram-negative bacteria, peptidoglycan, flagellin, and microbial nucleic acids (e.g., dsRNA or unmethylated CpG DNA). These components are recognized by the host's innate immune system through Pattern Recognition Receptors (PRRs), such as Toll-like receptors (TLRs) and NOD-like receptors (NLRs), to initiate an immune response against infection. In a drug discovery context, this entry is considered incorrect or too broad because it does not represent a single, defined molecular target like a specific enzyme or receptor. Instead, it describes a collective category of microbial products that can trigger various biological pathways. Therapeutic strategies typically focus on the specific host receptors that detect these components or the specific microbial enzymes responsible for their synthesis, rather than the broad components themselves.
Not applicable as this is a broad category of molecules rather than a specific therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Broad microbial components.